Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.
Brain Neoplasms
DRUG: MPC-6827
Maximum Tolerated Dose, 1 year|Pharmacokinetics, 1 year
Antitumor Activity, 2 years
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.